http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36643873

Outgoing Links

Predicate Object
contentType Randomized Controlled Trial|Clinical Trial, Phase III|Journal Article
endingPage 371
issn 2374-2437
issueIdentifier 3
pageRange 362-371
publicationName JAMA Oncology
startingPage 362
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_448c3d7a8b95445db230c0de0b6d375a
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_69731bb36a4061fbaf74a48f03dfbd8c
bibliographicCitation Ma CX, Suman VJ, Sanati S, Vij K, Anurag M, Leitch AM, Unzeitig GW, Hoog J, Fernandez-Martinez A, Fan C, Gibbs RA, Watson MA, Dockter TJ, Hahn O, Guenther JM, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken TJ, Wang Y, Rimawi MF, Weiss A, Winer EP, Hunt KK, Perou CM, Ellis MJ, Partridge AH, Carey LA. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01;10(3):362–71. PMID: 38236590; PMCID: PMC10797521.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8f3957111b5c3cfe9b7cd2f3c396023e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_56e66787d2570e7f0d985ee04d2a366f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d54f56f6eb7385fd6a4a8607e4ffd994
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d861ddb360f9c54c2ee1603201589c40
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d67c0ce3c08398c539fb3be1ce115a0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_04b2993e62c6e0c7e6c1b5e99ad1a51f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_87bdc306bc35a319425482d167f66ab6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2cd768bd92350c76f1820c2c32bb5bbb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e5559cd6ccfc5e29bf989236922c8c25
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fbd3c8de7e30a2bc7267ac2e99ac256d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9652e2c35608c834ca7126358fb13be8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d78c01d52b9c3b9cabdcc8319ac31936
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f3bd130b20c91261ed083311bcf7cf5a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d5a12cec60fce5b29bb96fb34e399a68
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_51d06a3c866417c736e7fd5527d939cc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_67ae5f02f6e4edf5d60ee609492fbdc9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e178943ca50786dabd46cf1e0e86d73
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ce2cd8934d1f2a4cd29dcac129bf4b4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8b1cc2d930a8831c74ac8ff4d15055e8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_40ba84bf38f02ec9e056874453ae13b7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b5a8c00cd44aa3072dbaa08622502273
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6be0229ffc34feeff915b11f0116469a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7eb289fad5e1237ae23f5c1811fabb6d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f6db8697f22fa82164e39aa5d0943d08
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_54f8fcbec2cb91ac743ceaa7eaa1af83
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ac3e8a08478364a8a337937703a81afc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_191209572d7e10a99e8c22c257d5e9af
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_220c7986b2be3e5de57b044fe29a50ef
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7425b7130d56f5edb3d00431791934b6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_13ced172fceaabef417823da28772eed
date 2024-03-01^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1001/jamaoncol.2023.6038
https://pubmed.ncbi.nlm.nih.gov/PMC10797521
https://pubmed.ncbi.nlm.nih.gov/38236590
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/43608
https://portal.issn.org/resource/ISSN/2374-2437
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial
discusses http://id.nlm.nih.gov/mesh/M0028048
http://id.nlm.nih.gov/mesh/M0018586
http://id.nlm.nih.gov/mesh/M0397101
http://id.nlm.nih.gov/mesh/M0238999
http://id.nlm.nih.gov/mesh/M0014878
http://id.nlm.nih.gov/mesh/M0021911
http://id.nlm.nih.gov/mesh/M0028859
http://id.nlm.nih.gov/mesh/M0495206
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D064726Q000188
http://id.nlm.nih.gov/mesh/D001943Q000473
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000077384Q000627
http://id.nlm.nih.gov/mesh/D020360
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D018719
http://id.nlm.nih.gov/mesh/D019394
http://id.nlm.nih.gov/mesh/D014230Q000009
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D000971Q000009
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D009570Q000009
http://id.nlm.nih.gov/mesh/D011960
http://id.nlm.nih.gov/mesh/D017698
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D000077267

Showing number of triples: 1 to 74 of 74.